FNA News and Press, Paragon 28 Inc. From 08/03/22

Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended June 30, 2022 and increased its 2022 revenue guidance. Financial Highlights ...

Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the second quarter 2022 after market close on Wednesday, August 3, 2022. The companyȁ...

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will be presenting at The Canaccord Genuity 42 nd Annual Growth Conference in Bost...

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced its new nationwide mobile training lab tour, for convenient, on-site surgeon training and education. This press release features multimedia. Vi...

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced further expansion of its hammertoe and soft-tissue portfolio with the launch of its TenoTac™ 2.0 Soft Tissue Fixation System. The TenoTac&#x...

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today an expansion of its soft-tissue portfolio with the launch of its Grappler™ Suture Anchor System. The Grappler™ Suture Anchor System p...

Paragon 28, Inc. (FNA) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Matt Bacso - Gilmartin Group Albert DaCosta - Co Founder, President and Chief Executive Officer Stephen Deitsch - Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sa...

Paragon 28 press release (NYSE:FNA): Q1 GAAP EPS of -$0.12 misses by $0.05. Revenue of $41.4M (+25.1% Y/Y) beats by $3.93M. For further details see: Paragon 28 GAAP EPS of -$0.12 misses by $0.05, revenue of $41.4M beats by $3.93M

Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended March 31, 2022 and updated its 2022 revenue guidance. Financial Highlights ...

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today an expansion of its hammertoe and soft-tissue portfolio with the launch of its Paratrooper™ Plantar Plate Repair System. The Paratrooper...